Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00810888 · ClinicalTrials.gov registry record · Phase 2

The Spot Sign for Predicting and Treating ICH Growth Study

A Phase 2 study of Intracerebral Hemorrhage, sponsored by University of Cincinnati.

Completed
Registry status
Phase 2
Development phase
92
Enrollment target
10
Study locations

NCT00810888: Completed Phase 2 study of Intracerebral Hemorrhage, sponsored by University of Cincinnati.

NCT00810888 is a Phase 2 study of Intracerebral Hemorrhage that has completed, run by University of Cincinnati. The registered enrollment target is 92 participants, below the 1,173-participant average among 29 other Intracerebral Hemorrhage trials with a reported enrollment target (92% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00810888, a Phase 2 study of Intracerebral Hemorrhage, has completed, sponsored by University of Cincinnati.

COMPLETED
Registry status
Phase 2
Development phase
92 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to determine if computed tomography angiography can predict which individuals with intracerebral hemorrhage will experience significant growth in the size of the hemorrhage. For individuals who are at high risk for hemorrhage growth, the study will compare the drug recombinant activated factor VII (rFVIIa) to placebo to determine the effect of rFVIIa on intracerebral hemorrhage growth.

Conditions Studied

Intracerebral Hemorrhage

Interventions

  • DRUG placebo
  • DRUG recombinant activated factor VII

Study Locations (10)

Pennsylvania

  • University of Pennsylvania - Philadelphia
  • University of Pittsburgh Medical Center - Pittsburgh

Arizona

  • St. Joseph's Hospital and Medical Center - Phoenix

California

  • University of California, San Diego - San Diego

Massachusetts

  • Massachusetts General Hospital - Boston

Missouri

  • Washington University - St Louis

Ohio

  • University of Cincinnati-Clinical Coordinating Center - Cincinnati

South Carolina

  • Medical University of South Carolina - Charleston

Alberta

  • University of Calgary - Calgary

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2010-11
Est. Completion 2016-04
Phase Phase 2

Sponsor

University of Cincinnati

245 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00810888

The ClinicalTrials.gov registry entry for NCT00810888 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,173-participant average among 29 other Intracerebral Hemorrhage trials with a reported enrollment target (92% lower). The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Intracerebral Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00810888 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Pennsylvania, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT00810888 about?

NCT00810888 is a clinical study titled "The Spot Sign for Predicting and Treating ICH Growth Study". The purpose of this study is to determine if computed tomography angiography can predict which individuals with intracerebral hemorrhage will experience significant growth in the size of the hemorrhage. For individuals who are at high risk for hemorrhage growth, the study will compare the drug recom...

What is the current status of trial NCT00810888?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2010-11. Estimated completion is 2016-04.

What conditions does trial NCT00810888 study?

This clinical trial studies the following conditions: Intracerebral Hemorrhage.

What interventions are being tested in trial NCT00810888?

The interventions under investigation include: placebo (DRUG), recombinant activated factor VII (DRUG).

Who is sponsoring clinical trial NCT00810888?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00810888 being conducted?

This trial has 10 study locations across Arizona, California, Massachusetts, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Intracerebral Hemorrhage

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Intracerebral Hemorrhage

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.